Molecular imaging in multiple myeloma — novel PET radiotracers improve patient management and guide therapy

  • Due to its proven value in imaging of multiple myeloma (MM), including staging, prognostication, and assessment of therapy response, 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) is utilized extensively in the clinic. However, its accuracy is hampered by imperfect sensitivity (e.g., so-called FDG-negative MM) as well as specificity (e.g., inflammatory processes), with common pitfalls including fractures and degenerative changes. Novel approaches providing a read-out of increased protein or lipid membrane syntheses, such as [11C]methionine and [11C]choline or the C-X-C motif chemokine receptor 4-targeting radiotracer [68Ga]Pentixafor, have already been shown to be suitable adjuncts or alternatives to FDG. In the present focused review, those imaging agents along with their theranostic potential in the context of MM are highlighted.

Download full text files

Export metadata


Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Author:Johannes von Hinten, Malte Kircher, Alexander Dierks, Christian H. Pfob, Takahiro Higuchi, Martin G. Pomper, Steven P. Rowe, Andreas K. Buck, Samuel Samnick, Rudolf A. Werner, Constantin LapaORCiDGND
Frontdoor URL
Parent Title (English):Frontiers in Nuclear Medicine
Publisher:Frontiers Media S.A.
Date of first Publication:2022/02/25
Publishing Institution:Universität Augsburg
Release Date:2022/09/06
Tag:[18F]fluorodeoxyglucose; [C11]methionine; [C11]choline; [68Ga]Pentixafor; [177Lu]Penthixather; CXCR4; theranostics
First Page:801792
Institutes:Medizinische Fakultät
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Nuklearmedizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):CC-BY 4.0: Creative Commons: Namensnennung (mit Print on Demand)